Last updated on July 2019

Evaluation of TTP399 in Patients With Type 1 Diabetes


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.

Clinical Study Identifier: NCT03335371

Find a site near you

Start Over

Site 01

Chapel Hill, NC United States
  Connect »

Site 05

Escondido, CA United States
  Connect »

Site 13

Aurora, CO United States
  Connect »

Site 06

Atlanta, GA United States
  Connect »

Site 10

West Des Moines, IA United States
  Connect »

Site 16

Asheville, NC United States
  Connect »

Site 03

Durham, NC United States
  Connect »

Site 04

Morehead City, NC United States
  Connect »

Site 12

Wilmington, NC United States
  Connect »

Site 02

Winston-Salem, NC United States
  Connect »

Site 11

Norman, OK United States
  Connect »

Site 07

Greer, SC United States
  Connect »

Site 08

Dallas, TX United States
  Connect »

Site 14

Seattle, WA United States
  Connect »

AMCR Institute

Escondido, CA United States
  Connect »

Atlanta Diabetes Associate

Atlanta, GA United States
  Connect »

Rocky Mountain Diabetes Center

Idaho Falls, ID United States
  Connect »

Iowa Diabetes Research

West Des Moines, IA United States
  Connect »

UNC Diabetes Care Center

Chapel Hill, NC United States
  Connect »

Diabetes & Endocrinology Consultants

Morehead City, NC United States
  Connect »

PMG Research of Wilmington

Wilmington, NC United States
  Connect »

Wake Forest

Winston-Salem, NC United States
  Connect »

Intend Research

Norman, OK United States
  Connect »

USC Westside Center for Diabetes

Beverly Hills, CA United States
  Connect »